Enlivex Therapeutics Ltd. Accounts Receivables 2011-2025 | ENLV

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Enlivex Therapeutics Ltd.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	-	28 K	52 K	145 K	93 K	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
145 K	28 K	79.5 K

Quarterly Accounts Receivables Enlivex Therapeutics Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16 K	-	-	-	28 K	-	-	-	52 K	-	-	-	145 K	-	-	-	93 K	-	-	-	26 K	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
145 K	16 K	60 K

Accounts Receivables of other stocks in the Biotechnology industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
Amphastar Pharmaceuticals AMPH	136 M	$ 25.27	-2.43 %	$ 1.22 B	USA
Alpine Immune Sciences ALPN	392 K	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	1.78 M	$ 4.75	1.61 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	318 K	$ 3.26	-3.12 %	$ 252 M	USA
Acasti Pharma ACST	802 K	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	821 K	-	-15.15 %	$ 60.3 M	Britain
Albireo Pharma ALBO	3.27 M	-	-0.23 %	$ 916 M	USA
Ayala Pharmaceuticals AYLA	234 K	-	-	$ 7.46 M	Israel
Anika Therapeutics ANIK	36 M	$ 9.57	0.84 %	$ 140 M	USA
Brickell Biotech BBI	1.13 M	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	676 M	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	205 K	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	18.5 M	-	-7.31 %	$ 87 M	USA
Benitec Biopharma BNTC	33 K	$ 12.05	-7.06 %	$ 496 M	USA
Aytu BioScience AYTU	31.2 M	$ 2.34	2.59 %	$ 14.7 M	USA
Arena Pharmaceuticals ARNA	1.65 M	-	-6.81 %	$ 3.04 B	USA
Aptorum Group Limited APM	62.2 K	$ 1.29	-3.01 %	$ 7.03 M	China
Baudax Bio BXRX	335 K	-	0.59 %	$ 63 K	USA
Catalyst Biosciences CBIO	1.82 M	$ 14.01	-8.49 %	$ 922 M	USA
ChromaDex Corporation CDXC	5.23 M	-	-0.88 %	$ 598 M	USA
Axon Enterprise AXON	18.1 M	$ 566.18	-2.56 %	$ 42.9 B	USA
Cerus Corporation CERS	29.8 M	$ 2.16	0.47 %	$ 399 M	USA
Caladrius Biosciences CLBS	900 K	-	-16.75 %	$ 25.8 M	USA
Clovis Oncology CLVS	26.9 M	-	-7.23 %	$ 13 M	USA
Biogen BIIB	1.4 B	$ 174.42	1.11 %	$ 25.4 B	USA
Celldex Therapeutics CLDX	700 K	$ 27.36	-2.09 %	$ 1.76 M	USA
Deciphera Pharmaceuticals DCPH	32 M	-	-	$ 2.18 B	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	308 M	$ 11.54	0.87 %	$ 746 M	USA